Dernières nouvelles pour Sigma Lithium (NASDAQ:SGML) Stock

Sigma Lithium

Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.

Sigma Lithium Corporation - common shares

Sigma Lithium Corp

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading lower Wednesday after the electric vehicle maker reported its fifth consecutive month of declining <a href="https://www.benzinga.com/markets/tech/25/06/46087914/teslas-europe-sales-slide-for-5th-straight-month-elon-musk-led-ev-giants-market-share-shrinks-to-1-3">sales in the European market</a>.
What To Know: Tesla's new vehicle sales fell 27.9% year-over-year in Europe last month, despite the broader electric vehicle segment growing by 27.2% in the region, according to Reuters, citing data from the European Automobile Manufacturers Association (ACEA).
The company's latest Model Y update has yet to reverse the downward trend for Tesla that started when buyers began protesting CEO Elon Musk&#8217;s political involvement. 
The broader European market saw a modest 1.9% increase in overall new car sales last month, while Tesla's market share in Europe dropped to just 1.2%, compared to 1.8% in the same month last year.
Tesla's performance diverged sharply from that of its competitors. Reuters reported that legacy automakers and Chinese EV firms continued to gain ground, particularly in the lower-cost segment. 
The decline highlights ongoing challenges for Tesla in Europe, including rising competition from state-backed Chinese manufacturers like SAIC, pricing pressure across the EV market and shifting consumer sentiment. 
The decline in Tesla shares on Wednesday comes after shares <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46058796/tesla-stock-is-surging-today-whats-driving-the-momentum">moved higher</a> to start the week following the company&#8217;s &#8220;successful&#8221; robotaxi launch in Austin. 
Analysts had mixed reactions to the event with Wedbush's Dan Ives predicting that the rollout will accelerate as he suggested that Tesla&#8217;s autonomous arm is worth $1 trillion alone. Ives maintained an Outperform rating on Tesla with a price target of $500.
Meanwhile, UBS maintained a Sell rating following the robotaxi launch and lifted its price target to $215, while Guggenheim reiterated a Sell rating with a price target of $175.
TSLA Price Action: Tesla shares were down 4.14% at $326.40 at the time of publication Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46099022/best-ai-stocks-nvidia-semiconductors-top-performers">The AI Rally Just Flipped—These Stocks Are Now Outgunning Nvidia</a></li>
</ul>
Image via Shutterstock.

News

TSLA

Tesla Stock Is Sliding Wednesday: What's Going On?

Oppenheimer analyst Noah Kaye maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Outperform and raises the price target from $251 to $255.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Waste Management, Raises Price Target to $255

Carlyle Secured Lending's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NYSE">CGBD</a>) short percent of float has fallen 3.92% since its last report. The company recently reported that it has 357 thousand shares sold short, which is 0.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.14 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Carlyle Secured Lending Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750870884_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carlyle Secured Lending has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carlyle Secured Lending's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Carlyle Secured Lending's peer group average for short interest as a percentage of float is 2.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CGBD

What Does the Market Think About Carlyle Secured Lending?

Starbucks's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>) short percent of float has fallen 12.44% since its last report. The company recently reported that it has 38.34 million shares sold short, which is 3.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Starbucks Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750870879_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Starbucks has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Starbucks's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Starbucks's peer group average for short interest as a percentage of float is 9.64%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SBUX

Peering Into Starbucks's Recent Short Interest

In the current session, Watsco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) is trading at $429.67, after a 0.36% drop. Over the past month, the stock decreased by 4.95%, and in the past year, by 8.87%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1750870878_0.png" alt="Past Year Chart" />

<h3>Comparing Watsco P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Watsco has a lower P/E than the aggregate P/E of 105.09 of the Trading Companies &amp; Distributors industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750870879_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Watsco

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has risen 21.28% since its last report. The company recently reported that it has 5.33 million shares sold short, which is 3.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750870874_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 7.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VEEV

What's Driving the Market Sentiment Around Veeva Systems?

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company&#8217;s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46091315/viking-therapeutics-announces-initiation-of-phase-3-obesity-clinical-program-with-glp-1gip-agonist" rel="noreferrer noopener">polypeptide (GIP) receptors</a>.
VK2375 is being developed in oral and subcutaneous formulations for metabolic <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">disorders such as obesity</a>.
The VANQUISH Phase 3 program includes two studies evaluating VK2735: one in adults with obesity and one in obese or overweight adults with type 2 diabetes.&nbsp;
Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" target="_blank" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a>
VANQUISH-1 study: The study will target enrollment of approximately 4,500 obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) adults with at least one weight-related co-morbid condition.
VANQUISH-2 study: The study will target enrollment of approximately 1,100 adults with type 2 diabetes who are obese or overweight. 
Participants in both trials will be randomized to one of four weekly treatment arms: VK2735 7.5 mg, VK2735 12.5 mg, VK2735 17.5 mg, and placebo, slightly higher than the currently approved Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound doses of 5 mg, 10 mg and 15 mg.
The trials&#8217; primary endpoint is the percent change in body weight from baseline for participants receiving VK2735 compared to placebo after 78 weeks of treatment.
Secondary and exploratory endpoints will evaluate additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction.&nbsp;
Each study will include an open-label extension, allowing participants to continue receiving treatment after the primary dosing period is completed.
In 2024, Viking announced topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity.
The VENTURE trial successfully achieved its primary and all secondary endpoints, with patients receiving VK2735 demonstrating clinically meaningful reductions in body weight compared with placebo.
Patients receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%, and statistically significant reductions in mean body weight relative to placebo, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">ranging up to 13.1%</a>.
Differences compared to placebo were statistically significant for all doses starting at week one and were maintained throughout the study.
In addition, results from follow-up visits four and seven weeks after the last dose of VK2735 was administered showed that cohorts receiving VK2735 maintained the majority of their weight loss through the seven-week follow-up visit after administering the final dose.
VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with most observed adverse events (AEs) being reported as mild or moderate.
Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo. Of gastrointestinal (GI) related AEs, 95% were reported as mild or moderate.
Why it Matters: William Blair notes some obesity experts said that insurance companies often won't cover certain &#8220;non-standard&#8221; Zepbound doses like 2.5 mg, 7.5 mg and 12.5 mg, even though these may be the best long-term doses for some patients.
While large academic hospitals with specialized reimbursement teams can usually work around this issue, smaller or community clinics may benefit from approving these in-between doses, as it could make treatment more accessible for more patients.
Analyst Andy Hsieh expects that 17.5 mg VK2735 could contribute to additional weight loss over 15 mg Zepbound and surmises there could be a potential ceiling effect when it comes to increasingly higher doses of Zepbound or VK2735.
&#8220;We continue to believe that Viking's obesity franchise offers a unique set of attractive qualities that will be viewed favorably in the lens of big pharma from an M&amp;A perspective&#8230;,&#8221; William Blair analyst wrote on Wednesday.
VKTX Price Action: VKTX stock is down 1% at $26.68 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46097698/bumble-is-breaking-up-with-30-staff-investors-swipe-right" target="_blank" rel="noreferrer noopener">Bumble Is &#8216;Breaking Up&#8217; With 30% Staff, Investors Swipe Right</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Movers

General

VKTX

What's Going On With Viking Therapeutics Stock On Wednesday?

CNBC Halftime Report Final Trades: Taiwan Semiconductor Manufacturing, Advanced Micro Devices, American Express

Raymond James analyst Patrick Tyler Brown maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Outperform and lowers the price target from $275 to $260.

Raymond James Maintains Outperform on FedEx, Lowers Price Target to $260

Raymond James analyst Brian Gesuale reiterates AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) with a Strong Buy and raises the price target from $200 to $225.

Reiteration

AVAV

Raymond James Reiterates Strong Buy on AeroVironment, Raises Price Target to $225

Raymond James analyst Sam Darkatsh downgrades GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades GMS to Market Perform

WIIM

BOOM

FANG

NINE

RCON

Shares of oil-related companies are trading higher. The commodity may be seeing a price increase due to a rebound after falling amid escalating Iran-Israel tensions.

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 11.64% on an annualized basis producing an average annual return of 26.14%. Currently, Williams Companies has a market capitalization of $74.26 billion. 
Buying $1000 In WMB: If an investor had bought $1000 of WMB stock 5 years ago, it would be worth $3,306.21 today based on a price of $60.82 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750870312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Kellanova Now Expects Merger With Mars To Close Towards End Of 2025

<a href="https://apnews.com/article/getty-images-stability-ai-copyright-trial-stable-diffusion-7208c729fb10c1f133cb49da2065d72a">https://apnews.com/article/getty-images-stability-ai-copyright-trial-stable-diffusion-7208c729fb10c1f133cb49da2065d72a</a>

GETY

'Getty Drops Copyright Allegations In UK Lawsuit Against Stability AI'- AP News

NVDA

NVIDIA shares are trading higher after Loop Capital maintained a Buy rating and raised its price target from $175 to $250.

Morgan Stanley analyst Erik Woodring maintains TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) with a Overweight and raises the price target from $145 to $155.

Morgan Stanley Maintains Overweight on TD Synnex, Raises Price Target to $155

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.2% on Wednesday.
The Dow traded down 0.18% to 43,011.70 while the NASDAQ gained 0.20% to 19,953.27. The S&amp;P 500 also rose, gaining, 0.02% to 6,093.14.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a>
Leading and Lagging Sectors Information technology shares jumped by 0.8% on Wednesday.
In trading on Wednesday, real estate stocks fell by 1.3%.
Top Headline
U.S. crude oil inventories declined by 5.836 million barrels in the week ended June 20, compared to market estimates of a 0.75 million barrel fall.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares shot up 59% to $0.2968 after the company announced FDA clearance of its investigational new drug application for REYOBIQ to treat childhood brain cancer.</li>
<li>Shares of QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) got a boost, surging 36% to $5.88 after the company achieved a key 2025 milestone by successfully integrating its advanced Cobra separator process into baseline cell production.</li>
<li>SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares were also up, gaining 49% to $0.5362 after the company announced it is taking strategic actions to regain Nasdaq compliance.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Lifeward Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) shares dropped 38% to $0.6015 after the company announced the pricing of a $2.6 million public offering of 4 million shares and warrants at a combined price of $0.65 per share and associated ordinary warrant.</li>
<li>Shares of Torrid Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) were down 37% to $3.1900 after the company announced the pricing of a secondary offering of 10 million shares at $3.50 per share.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) was down, falling 17% to $8.01 after the company announced the pricing of its $40 million public offering of 5 million shares at $8.00 per shares.</li>
</ul>
Commodities In commodity news, oil traded up 2.5% to $65.99 while gold traded up 0.3% at $3,343.80.
Silver traded up 1% to $36.070 on Wednesday, while copper rose 0.7% to $4.9605.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.74%, while Spain's IBEX 35 Index fell 1.59%. London's FTSE 100 fell 0.46%, Germany's DAX 40 fell 0.61% and France's CAC 40 slipped 0.76% during the session.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei gaining 0.39%, Hong Kong's Hang Seng Index gaining 1.23%, China's Shanghai Composite rising 1.04% and India's BSE Sensex rising 0.85%.
Economics
<ul class="wp-block-list">
<li>Sales of new single-family homes in the U.S. dipped by 13.7% from the previous month to an annualized rate of 623,000 units in May.</li>
<li>U.S. building permits declined by 2% to an annualized rate of 1.394 million in May.</li>
<li>U.S. volume of mortgage applications increased by 1.1% from the previous week in the week ending June 20.</li>
<li>U.S. crude oil inventories declined by 5.836 million barrels in the week ended June 20, compared to market estimates of a 0.75 million barrel fall.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46093500/how-to-earn-500-a-month-from-micron-technology-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Micron Technology Stock Ahead Of Q3 Earnings</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

ALLT

CURV

LFWD

PSTV

Crude Oil Rises Sharply; Torrid Holdings Shares Plunge

Ford Motor To Require Most Salaried Staff In Office 4 Days A Week Starting September 1

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1604" title="https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1604">https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1604</a>

Reported June 24, 2025: EU Antitrust Regulators To Investigate Mars' $36B Takeover Of Kellanova; The Transaction Could Lead To Higher Prices For Consumers Due To Mars' Increased Negotiating Power Towards Retailers In The European Economic Area; EU Sets Oct 31 2025 Deadline For Decision On Deal

Small Cap

Press Releases

SIGMA LITHIUM ANNOUNCES SHIPMENT THIS WEEK OF 22,650T OF QUINTUPLE ZERO GREEN LITHIUM TO ABU DHABI'S IRH

SIGMA LITHIUM EXCEEDS 4Q2024 TARGETS WITH 75,000T OF QUINTUPLE ZERO GREEN LITHIUM PRODUCED; POSITIONED TO SURPASS 270,000T IN 2025

Opinion

Lithium's Role in the Energy Revolution to Regain Momentum in 2025

SIGMA LITHIUM ADVANCES CONSTRUCTION TO DOUBLE CAPACITY AND PROVIDES FY2024 PREVIEW AND FY2025 GUIDANCE

SIGMA LITHIUM APPOINTS CIO FROM PROMINENT SAUDI ARABIAN INDUSTRIAL CONGLOMERATE AS NEW INDEPENDENT BOARD MEMBER; TO RELEASE FY2024 RESULTS ON MARCH 31, 2025

SIGMA LITHIUM REPORTS 4Q24 AND FY24 RESULTS: STRONG MARGIN GENERATION, RECORD PRODUCTION AND SIGNIFICANT COST REDUCTIONS

SIGMA LITHIUM ACHIEVES 1Q25 PRODUCTION TARGET WITH 68,300t OF QUINTUPLE ZERO GREEN LITHIUM, MAINTAINING CASH GENERATION, COSTS IN LINE WITH GUIDANCE

SIGMA LITHIUM TO RELEASE FIRST QUARTER 2025 RESULTS ON MAY 14, 2025

SIGMA LITHIUM ANNOUNCES 1Q25 PREVIEW: OUTPERFORMS TARGETS, OPERATIONAL PROFITABILITY, 24% EBITDA MARGIN

SIGMA LITHIUM REPORTS 1Q25 RESULTS: STRONG MARGINS, COST OUTPERFORMANCE AND PRODUCTION ABOVE TARGET

ALTM

ATLX

LISMF

SGML

TSX:LAC

TSXV:LIS

TSXV:SGML

B of A Securities

BMO Capital

Canaccord Genuity

Screenshot 2024-12-06 at 6.51.59 PM

From Record Shipments To Full Production Capacity, Sigma Lithium Is Ending The Year With Reason To Cheer

Screenshot 2024-11-19 at 6.24.48 PM

Sigma Lithium Achieves Production Guidance Amid Growing Demand, Lower Costs

Screenshot 2024-09-27 at 5.33.27 PM

Emerging Markets

FFMGF

LIFFF

LRSRF

PAN GLOBAL RESOURCE INC by Pan Global Resource, Inc.

PGZFF

TSX:CF

TSX:MPVD

TSXV:SM

Could Lithium Prices Be Near The Bottom Of The Cycle? This Company Believes So – A Look At How Li-FT Power Stacks Up

Screenshot 2024-09-20 at 8.26.27 PM

Sigma Lithium Maintains Near-Monthly Shipment Cadence With Latest Sale Of Green Lithium To Mitsubishi, Deepens Management Bench With New CFO

Screenshot 2024-09-03 at 6.08.17 PM

Sigma Lithium Secures Development Loan To Build Second Greentech Lithium Plant, Says It&#39;s On Track To Boost Production As A Result

Screenshot 2024-08-23 at 5.29.43 PM

Movers & Shakers

Sigma Lithium Q2 Results: Production Boosted, Customer Base Expanded, Guided Cost Structure Achieved Ahead Of Schedule

Screenshot 2024-03-22 at 8.20.01 PM

Atlas Lithium (NASDAQ: ATLX) Announces Appointment Of Seasoned Lithium Expert Brian Talbot As Chief Operating Officer

Screenshot 2024-03-19 at 9.31.11 PM

BYDDY

Atlas Lithium (NASDAQ: ATLX): The Under-The-Radar Company Partnered With Suppliers To The Largest EV Makers Globally

Comments

Sigma Lithium

Actualités

Dernières nouvelles pour Sigma Lithium (NASDAQ:SGML) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL